Personalized cancer vaccines are a complex cocktail developed directly from the patient’s own cancer cells and aim to help the immune system better recognize and destroy them. Our therapeutic vaccinations are uniquely crafted for each patient using a fresh blood sample, in which we can identify the patient’s unique, living cancer cells and the DNA found within them.
This therapy works by introducing a pool of antigens obtained from the individual’s cancer cells back into the bloodstream, thus stimulating the immune system. The immune system now has the blueprint it needs to target and eliminate remaining cancerous cells anywhere in the body!
Administration of Vaccines
Our tailor-made injectable vaccinations only take 2-3 weeks to craft after the patient’s blood is collected. Treatment consists of 6 injections over the course of 12 weeks. We deliver the first injection at our clinic or we travel to your location, demonstrating the appropriate technique to the patient or their caretaker. The remaining vaccinations are self-administered in the patient’s home. These injectable treatments may be transported internationally over dry ice and must be stored in a freezer once at their final destination.
Patients have seen cancer remission as soon as 3 weeks after completing their course of vaccinations! Optimum results may take longer for some, but possibilities and expectations can be discussed with Joachim Drevs, MD, Ph.D., Medical Director at Unifontis.
For compromised patients or patients too sick to travel, we offer our personalized vaccine therapy as an internationally-delivered service. Unifontis nurses will travel directly to your doorstep for complete blood work and vaccination delivery!
History of Vaccine Therapy
Traditionally, vaccinations are known to be given to healthy individuals to prevent them from catching a particular illness such as measles, chickenpox or even the flu. However, there are also therapeutic vaccines that may be given to individuals with cancer to strengthen their immune response and help eradicate the illness from within.
The first vaccine in history was developed in 1796 to prevent the spread of smallpox. Nowadays there are many vaccinations widely available to protect ourselves and others from deadly diseases.
Personalized vaccines against cancer have been analyzed and studied since 1999 with phenomenal scientific support. However, due to the lack of pharmaceutical backing and financial lobbying issues, vaccine therapies never became the industry standard.
Depending on the patient’s chosen treatment plan, they will stay in our clinic between 3 days and 3 weeks. Patients may opt for personalized vaccines only, but our standard of treatment consists of three core therapies with the highest chance for success. In addition to therapeutic cancer vaccines, our patients may also participate in therapeutic hyperthermia and aspirin therapy.
Compromised patients or patients too sick to travel may participate in vaccination and aspirin therapy in their homes. Therapeutic hyperthermia is only available in our German clinic. Click here to learn more about UNIFONTIS’ Supplemental Therapies.
Therapeutic Cancer Vaccine Studies
- Guo, Chunqing et al. “Therapeutic cancer vaccines: past, present, and future.” Advances in cancer research vol. 119 (2013): 421-75. doi:10.1016/B978-0-12-407190-2.00007-1
- Dillman R. et al. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm. 2004 Oct;19(5):581-8.
- Ratnavelu K. et al. Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report. Oncol Lett. 2013 May;5(5):1457-1460. Epub 2013 Mar 12.
- Demytra Mitsis et al. Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. Sarcoma. 2016; 2016: 9757219. Published online 2016 Sep 14. doi: 10.1155/2016/9757219
- Michael J. Nathenson, et al. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist. 2018 Jan; 23(1): 71–83. Published online 2017 Sep 21. doi: 10.1634/theoncologist.2016-0025
- P. D’Angelo et al. Sarcoma Immunotherapy: Past Approaches and Future Directions. Sarcoma. 2014; 2014: 391967. Published online 2014 Mar 20. doi: 10.1155/2014/391967. Correction in: Sarcoma.